Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-10-08
Yong‐Chen Lu
Federal Grant PI
High Impact
Assistant Professor (Tenure Track)
Also affiliated: National Institutes of Health (2013–2023); University Health Network (2007–2011); University of Toronto (2007–2009); Ludwig Cancer Research (2017); University of Arkansas Medical Center (2025); Princess Margaret Cancer Centre (2022); Bristol-Myers Squibb (United States) (2017); de Duve Institute (2017); Ludwig Cancer Research (2017); National Cancer Institute (2015); Ludwig Cancer Research (2017); National Cancer Institute (2013–2023); ORCID (2021); Center for Cancer Research (2022); National Yang Ming University (2014); Campbell Family Institute for Breast Cancer Research (2007–2009); University of Colorado Denver (2009); UCLouvain (2017)
Pathology, College of Medicine
27 h-index
105 pubs
12,777 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Yong-Chen Lu's research investigates the role of T-cell responses in cancer immunotherapy, particularly focusing on identifying and targeting tumor-specific antigens. His work explores how somatic mutations within cancer cells can be recognized by T-cells, leading to anti-tumor immune responses. This has included studies on the immunogenicity of these mutations in various human cancers, such as epithelial and gastrointestinal cancers, and the identification of mutated antigens that elicit durable tumor regressions.
Dr. Lu is the Principal Investigator on an NIH/National Cancer Institute grant totaling $727,264, focused on understanding and enhancing T-cell responses to high-risk human papillomaviruses. His scholarship metrics include an h-index of 28, with 89 publications and over 12,771 citations, reflecting a highly cited researcher designation. He leads a research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Mayumi Nakagawa and Teresa Evans.
Metrics
- h-index: 27
- Publications: 105
- Citations: 12,777
Positions
-
Assistant Professor (Tenure Track) 2021–presentUniversity of Arkansas for Medical Sciences Pathology, College of Medicine Institutional directory
-
Staff Scientist 2016–2021National Cancer Institute Surgery Branch ORCID
-
Research Fellow 2014–2016National Cancer Institute Surgery Branch ORCID
-
Postdoctoral Fellow (Supervisor: Dr. Steven A. Rosenberg. Mentor: Dr. Paul F. Robbins) 2009–2014National Cancer Institute Surgery Branch ORCID
Selected Publications
-
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence (2026)
-
Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
Isolation of mitochondrial mutation-specific T cell receptors (2025)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation (2025)
-
376 Inhibition of GSK3β-mediated 53BP1 T334 phosphorylation in T cells enhances infiltration and cytotoxicity against head and neck squamous cell carcinoma (2024)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
Deciphering CD4<sup>+</sup> T cell‐mediated responses against cancer (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
Federal Grants 1 $727,264 total
NIH
Contact PI
Jul 2010 - Jun 2027
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Developing T cell-based immunotherapy targeting breast cancer antigen FBXO39 ABCRP Principal Investigator
- Developing CD4 T cell-based immunotherapy for breast cancer ABCRP Principal Investigator
- Defining tumor infiltrating B cells and their role in the modulation of TIL immunotherapy The Mark Foundation for Cancer Research via H Lee Moffitt Cancer Center & Research Institute Co-Investigator
- A pilot study of developing T cell-based cancer immunotherapies for African American and Hispanic populations TRI Principal Investigator
Collaboration Network
Top Collaborators
Teresa Evans
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Charles M. Quick
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Isolation of mitochondrial mutation-specific T cell receptors
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure
Jasmine Crane
University of Arkansas for Medical Sciences
5 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Nadia Darwish
University of Arkansas for Medical Sciences
5 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
5 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Anna Pasetto
Oslo University Hospital (NO)
4 shared publications
- Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
- Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy
- Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation
- Editorial: Personalized immunotherapy for cancer
Takeo Shibata
Kanazawa Medical University
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Hannah Coleman
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Mayumi Nakagawa
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
4 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
David W. Ussery
University of Arkansas for Medical Sciences
4 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Keanna Marsh
University of Arkansas for Medical Sciences
4 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Sumit K. Shah
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Benjamin J. Lieblong
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Steven R. Post
University of Arkansas Medical Center
3 shared publications
In database
- Isolation of mitochondrial mutation-specific T cell receptors
- Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients
- Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure
Similar Researchers
Based on overlapping research topics
Brandy Ree
Arkansas Colleges of Health Education
Immune Response and Inflammation
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Haihong Zhang
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Thomas J. Kelly
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Abby Geis
Immune Response and Inflammation
Cancer-related molecular mechanisms research
Disease Mechanisms Research
Alexis Danekas
Immune Response and Inflammation
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Nicholas Callais
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research